# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Guggenheim analyst Brad Canino initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Pri...
Oppenheimer analyst Matthew Biegler maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Outperform and maintains $22 price ...
JP Morgan analyst Anupam Rama maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Overweight and raises the price target fr...
Citigroup analyst Yigal Nochomovitz maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and raises the price target fro...
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate ...
Goldman Sachs analyst Richard Law maintains Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and lowers the price target from ...